© 2023 WSHU
NPR News & Classical Music
Play Live Radio
Next Up:
Available On Air Stations
Stories and information in our region on the COVID-19 pandemic.

Yale New Haven No Longer Recommends Hydroxychloroquine

John Locher
Clinical trials of hydroxychloroquine for COVID-19 have shown a lack of benefits for inpatients at Yale hospitals.

Yale New Haven Health System stopped recommending the anti-malaria drug hydroxychloroquine as a coronavirus therapy this week. 

Dr. Thomas Balcezak, chief medical officer of Yale Health, says some hospitalized COVID-19 patients received the drug as a trial under close supervision, but they hadn’t shown improvement.

“Side effects are rare, and we have been monitoring patients to see if they have those side effects, but on balance, our guideline development team felt that given the lack of benefits and the potential side effects, we should remove it from possible therapy.”

Balcezak says trial tests have finished, and the hospital is not recommending people use hydroxychloroquine as outpatients, given rare but serious heart side effects. He says the drug has not been shown to prevent virus transmission – yet.

“We don’t believe that there is benefit for inpatients in using hydroxycholoroquine, and we just don’t know until these trials are completed about its use to prevent the transmission of the COVID-19 virus.”

The news comes as President Donald Trump announced he had been taking the drug to fight potential coronavirus transmission.

Yale's COVID-19 Adult Treatment Algorithm can be found here.

Read the latest on WSHU’s coronavirus coverage here.

Do you have questions you’d like WSHU to answer in local coverage of the coronavirus? Let us know via this survey.

Cassandra Basler, a former senior editor at WSHU, came to the station by way of Columbia Journalism School in New York City. When she's not reporting on wealth and poverty, she's writing about food and family.
Related Content